A recent study examining early outcomes of inferotemporal implantation of the Xen gel stent (AbbVie) suggests this novel approach may be an effective surgical alternative for glaucoma patients.

Researchers from the Mayo Clinic in Florida analyzed data from 69 eyes of 60 patients who underwent standalone ab externo Xen gel stent placement in the inferotemporal quadrant without conjunctival incision or tenonectomy. At an average follow-up of 2.4 months, mean intraocular pressure (IOP) was reduced by 39% from 19.41 mmHg to 11.85 mmHg (P<0.001). Additionally, the mean number of glaucoma medications decreased by 80%, from 3.76 to 0.74 (P<0.001). Complete success, defined as resolved complications and reduced medications, was achieved in 65% of eyes, with 46% becoming medication-free. However, 35% of eyes experienced persistent complications requiring additional interventions.

While these early results are promising, further research with longer follow-up periods is needed to fully assess the long-term efficacy and safety of this surgical approach in glaucoma management, the researchers concluded. The data were presented at the Association for Research in Vision and Ophthalmology annual meeting in May.